Abstract
Abstract:Nitazoxanide has been proven to be efficacious for the treatment of Clostridium difficile infection (CDI), but data is limited in peritoneal dialysis (PD) patients. This report details the successful utilization of nitazoxanide and probiotics to treat multirecurrent CDI in a PD patient. A 58-year-old woman was admitted with hypotension, nausea and vomiting attributed to metronidazole therapy for CDI, her third CDI treatment regimen in 3 months. During her admission, the patient developed CDI and was started on a 6-week regimen of nitazoxanide and probiotics to assist in re-establishing the colonic flora. The regimen was well tolerated and the patient remained disease free at follow up, four months later.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1):S32–S42.GerdingDN]]MutoCA]]OwensRCJrTreatment of Clostridium difficile infection.Clin Infect Dis200846S32-S422. McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 2007;27:1029–1039.McMaster-BaxterNL]]MusherDMClostridium difficile: recent epidemiologic findings and advances in therapy.Pharmacotherapy2007271029-10393. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716–2719.HechtDW]]GalangMA]]SambolSP&etal;In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004.Antimicrob Agents Chemother2007512716-27194. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41–e46.MusherDM]]LoganN]]BresslerAM&etal;Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.Clin Infect Dis200948e41-e465. Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59:705–710.MusherDM]]LoganN]]MehendirattaV&etal;Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.J Antimicrob Chemother200759705-7106. Rossignol JF. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment Pharmacol Ther 2006;24:887–894.RossignolJFNitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients.Aliment Pharmacol Ther200624887-8947. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913–1918.McFarlandLV]]SurawiczCM]]GreenbergRN&etal;A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.JAMA19942711913-19188. Pillai A, Nelson RL. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008;1:CD004611.PillaiA]]NelsonRLProbiotics for treatment of Clostridium difficile-associated colitis in adults.Cochrane Database Syst Rev20081CD004611
